Skip to main content

Table 2 Biologics used in the treatment of IMIDs

From: Cancer risk in immune-mediated inflammatory diseases (IMID)

Biologic Type of molecule IMIDs for which it is licensed
Infliximab (Remicade®) Chimeric monoclonal antibody against TNF RA, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease, plaque psoriasis
Adalimumab (Humira®) Human monoclonal antibody against TNF RA, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis
Golimumab (Simponi®) Human monoclonal antibody against TNF RA, psoriatic arthritis, ankylosing spondylitis
Certolizumab pegol (Cimzia®) Pegylated humanized Fab’ monoclonal antibody fragment against TNF RA, Crohn’s disease
Etanercept (Enbrel®) Fusion protein of two TNF receptor 2 extracellular domains and the Fc portion of human IgG RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
Tocilizumab (Actemra® or RoActemra®) Humanized monoclonal antibody against the interleukin-6 receptor Juvenile idiopathic arthritis, RA
Rituximab (Rituxan® or MabThera®) Chimeric anti-CD20 monoclonal antibody RA, granulomatosis with polyangiitis (Wegener)
Abatacept (Orencia®) Fusion of extracellular domain of human CTLA-4 and the Fc domain of IgG RA
Alefacept (Amevive®) Fusion of CD2-binding region of LFA-3 and the CH2 and CH3 domains of IgG1 Psoriasis
Anakinra (Kineret®) Recombinant, non-glycosylated human IL-1 receptor antagonist RA
\